DOCSLIB.ORG

Notice of Adoption to Amend Article 11

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Notice of Adoption to Amend Article 11 NEW YORK CITY DEPARTMENT OF HEALTH AND MENTAL HYGIENE BOARD OF HEALTH Notice of Adoption of Amendments to Articles 11 and 13 of the New York City Health Code In accordance with §1043(b) of the New York City Charter (the “Charter”) and pursuant to the authority granted to the Board of Health (the “Board”) by §558 of the Charter, a notice of intention to amend Articles 11 and 13 of the New York City Health Code (the “Health Code”) was published in the City Record on September 20, 2017 and a public hearing was held on October 25, 2017. Two written comments were received; no witnesses testified at the public hearing. In consideration of the comments, one change was made to the original proposal. At its meeting on XXX, 2018, the Board adopted the following resolution. Statement of Basis and Purpose The Department’s Division of Disease Control conducts disease surveillance and control activities for most of the diseases listed in Article 11 (Reportable Diseases and Conditions) of the Health Code. The Division of Disease Control also enforces Article 13 (Clinical Laboratories) of the Health Code, which regulates how laboratory tests must be performed and the reporting of test results. In addition, the Department must comply with various provisions of Part 2 of the New York State Sanitary Code, found in Title 10 of the New York Codes, Rules and Regulations, with respect to control of communicable diseases. To conduct more effective, timely, and complete disease surveillance and control, the Board is amending Health Code Articles 11 and 13 as follows: Hepatitis B Reporting The Board is amending Health Code §13.03(b)(3)(B) (previously §13.03(b)(3)(A)) to require laboratories to report all hepatitis B virus (HBV) DNA test results, including negative results. The Health Department previously required laboratories to report only positive HBV DNA results, in addition to other positive HBV test results. HBV DNA testing is performed on individuals who have tested positive for HBV. HBV DNA tests measure viral load and whether the patient has chronic (active) HBV, requiring treatment. For patients already diagnosed with chronic HBV, DNA test results provide important information regarding infectiousness, treatment eligibility, and risk for development of liver cancer. For patients being treated for HBV, DNA test results provide information regarding treatment outcome (i.e., the extent to which the patient cleared the infection). The number of HBV cases is rising nationally and in New York City. More than 100,000 New Yorkers are estimated to be living with chronic HBV, with 8,439 new cases diagnosed in 2016, an increase of 18.8% since 2013. The majority of individuals infected with HBV as adults will clear the virus on their own, but many New Yorkers will develop chronic HBV. Chronic HBV can lead to serious health issues, including cirrhosis and liver cancer. All persons with chronic HBV infection require linkage to care and regular monitoring for liver damage and other complications; a subset require treatment with antiviral medications. Without negative HBV DNA test results, the Health Department would have limited knowledge regarding whether patients who have tested positive for HBV are receiving appropriate follow-up testing and treatment. Mandated reporting of negative HBV DNA test results will allow the Health Department to estimate the proportion of New Yorkers infected with HBV who are appropriately tested and linked to care; identify gaps in access to care; develop targeted interventions to increase linkage to care and improve provider knowledge of HBV testing and treatment guidelines; and increase monitoring to reduce HBV-related morbidity and mortality. In consideration of a comment received, the proposed amendment has been modified to exempt blood bank laboratories and other laboratories that perform hepatitis B DNA tests on donated blood from the requirement to report negative and indeterminate hepatitis B DNA test results for such donated blood. Carbapenem-resistant Enterobacteriaceae Reporting The Board is amending Health Code §11.03(a) to require laboratories to report carbapenem-resistant Enterobacteriaceae (CRE), an emerging bacterial threat. CRE are a family of bacteria that are difficult to treat because they have high levels of resistance to many antibiotics including carbapenem antibiotics. Carbapenem antibiotics are often used as the last line of treatment for infections caused by highly resistant bacteria, including those in the Enterobacteriaceae family. As explained by the Centers for Disease Control and Prevention (CDC): “The emergence and dissemination of carbapenem resistance among Enterobacteriaceae in the United States represents a serious threat to public health. These organisms cause infections that are associated with high mortality rates and they have the potential to spread widely. Decreasing the impact of these organisms will require a coordinated effort involving all stakeholders including healthcare facilities and providers, public health, and industry.”1 CDC has designated CRE an “urgent” threat, the highest threat level in its list of antibiotic resistant threats in the United States.2 CRE infections are common in hospitals, nursing homes, and other healthcare settings. Patients whose care requires devices like ventilators, urinary catheters, or intravenous catheters, and patients who are taking long courses of certain antibiotics are most at risk for CRE infections.3 In 2015, hospitals in NYS reported 3,618 CRE cases via the CDC’s National Healthcare Safety Network (NHSN); 1,727 of these were reported by the 51 participating New York City facilities.4 As only hospitals submit CRE data to the NHSN, the number of CRE infections in New York is probably significantly larger. Mandated reporting will provide vital epidemiological information regarding incidence and evolution of CRE and assist in the identification of new strains, clusters, and outbreaks. This will enable the Department to help ensure infection control precautions are being taken. Mandated reporting of CRE is also aligned with recently released Council of State and Territorial 1 Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases. Facility Guidance for Control of Carbapenem-resistant Enterobacteriaceae (CRE). November 2015 Update – CRE Toolkit. https://www.cdc.gov/hai/pdfs/cre/cre-guidance-508.pdf. 2 Centers for Disease Control and Prevention. Antibiotic Resistant Threats in the United States, 2013. https://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf. 3 Centers for Disease Control and Prevention. Carbapenem-resistant Enterobacteriaceae in Healthcare Settings. CDC website. https://www.cdc.gov/hai/organisms/cre/index.html. 4 NYS Healthcare Associated Infections in New York State, 2015. Part 2: Technical Report. March 2017. 2 Epidemiologists guidelines.5 Based on a 2016 survey, 27 jurisdictions require some form of CRE reporting.6 Minor changes to other parts of §11.03(a) are being made for purposes of consistency. Statutory Authority The Board’s authority to promulgate these proposed amendments is found in Sections 556, 558, and 1043 of the New York City Charter (the “Charter”). Sections 558(b) and (c) of the Charter empower the Board to amend the Health Code and to include all matters to which the Department’s authority extends. Section 556 of the Charter provides the Department with jurisdiction to protect and promote the health of all persons in the City of New York. Section 1043 grants the Board rule-making authority. The rule is as follows: Note: New material is underlined. [Deleted material is in brackets.] “Shall” and “must” denote mandatory requirements and may be used interchangeably unless otherwise specified or unless the context clearly indicates otherwise. RESOLVED, that subdivision (a) of section 11.03 of Article 11 of the New York City Health Code, set forth in Title 24 of the Rules of the City of New York, be amended, to be printed together with explanatory notes to read as follows: (a) Cases and carriers affected with any of the following diseases and conditions of public health interest, and persons who at the time of their death were apparently so affected, must be reported to the Department as specified in this article: Amebiasis Anaplasmosis (Human granulocytic anaplasmosis) Animal bite, or exposure to rabies Anthrax Arboviral infections, acute (including but not limited to the following viruses: chikungunya virus, Zika virus, dengue virus, Eastern equine encephalitis virus, Jamestown Canyon virus, Japanese 5 Council of State and Territorial Epidemiologists. Infectious Disease Committee Position Statement 17-ID-04: Public Health Reporting and National notification of Carbapenemase Producing Carbapenem-Resistant Enterobacteriaceae for E. coli, Klebsiella spp. and Enterobacter spp. July 2017. 6 Council of State and Territorial Epidemiologists. State Reportable Conditions Assessment (SRCA). http://srca.querytool.cste.org/. 3 encephalitis virus, La Crosse virus, Powassan virus, Rift Valley fever virus, St. Louis encephalitis virus, Western or Venezuelan equine encephalitis virus, West Nile virus and yellow fever) Babesiosis Botulism (including infant, foodborne and wound botulism) Brucellosis (undulant fever) Campylobacteriosis Chancroid Chlamydia trachomatis infections Cholera Creutzfeldt-Jakob Disease Cryptosporidiosis Cyclosporiasis Diphtheria Drownings, defined as the process of experiencing respiratory impairment from submersion/immersion in liquid whether
Load more

Recommended publications
  • Identification of Glucose Non-Fermenting Gram Negative Rods
    UK Standards for Microbiology Investigations Identification of Glucose Non-Fermenting Gram Negative Rods REVIEW UNDER Issued by the Standards Unit, Microbiology Services, PHE Bacteriology – Identification | ID 17 | Issue no: 2.2 | Issue date: 11.03.14 | Page: 1 of 24 © Crown copyright 2014 Identification of Glucose Non-Fermenting Gram Negative Rods Acknowledgments UK Standards for Microbiology Investigations (SMIs) are developed under the auspices of Public Health England (PHE) working in partnership with the National Health Service (NHS), Public Health Wales and with the professional organisations whose logos are displayed below and listed on the website http://www.hpa.org.uk/SMI/Partnerships. SMIs are developed, reviewed and revised by various working groups which are overseen by a steering committee (see http://www.hpa.org.uk/SMI/WorkingGroups). The contributions of many individuals in clinical, specialist and reference laboratories who have provided information and comments during the development of this document are acknowledged. We are grateful to the Medical Editors for editing the medical content. For further information please contact us at: Standards Unit Microbiology Services Public Health England 61 Colindale Avenue London NW9 5EQ E-mail: [email protected] Website: http://www.hpa.org.uk/SMI UK Standards for Microbiology Investigations are produced in association with: REVIEW UNDER Bacteriology – Identification | ID 17 | Issue no: 2.2 | Issue date: 11.03.14 | Page: 2 of 24 UK Standards for Microbiology Investigations | Issued by the Standards Unit, Public Health England Identification of Glucose Non-Fermenting Gram Negative Rods Contents ACKNOWLEDGMENTS .......................................................................................................... 2 AMENDMENT TABLE ............................................................................................................. 4 UK STANDARDS FOR MICROBIOLOGY INVESTIGATIONS: SCOPE AND PURPOSE ......
    [Show full text]
  • Table S4. Phylogenetic Distribution of Bacterial and Archaea Genomes in Groups A, B, C, D, and X
    Table S4. Phylogenetic distribution of bacterial and archaea genomes in groups A, B, C, D, and X. Group A a: Total number of genomes in the taxon b: Number of group A genomes in the taxon c: Percentage of group A genomes in the taxon a b c cellular organisms 5007 2974 59.4 |__ Bacteria 4769 2935 61.5 | |__ Proteobacteria 1854 1570 84.7 | | |__ Gammaproteobacteria 711 631 88.7 | | | |__ Enterobacterales 112 97 86.6 | | | | |__ Enterobacteriaceae 41 32 78.0 | | | | | |__ unclassified Enterobacteriaceae 13 7 53.8 | | | | |__ Erwiniaceae 30 28 93.3 | | | | | |__ Erwinia 10 10 100.0 | | | | | |__ Buchnera 8 8 100.0 | | | | | | |__ Buchnera aphidicola 8 8 100.0 | | | | | |__ Pantoea 8 8 100.0 | | | | |__ Yersiniaceae 14 14 100.0 | | | | | |__ Serratia 8 8 100.0 | | | | |__ Morganellaceae 13 10 76.9 | | | | |__ Pectobacteriaceae 8 8 100.0 | | | |__ Alteromonadales 94 94 100.0 | | | | |__ Alteromonadaceae 34 34 100.0 | | | | | |__ Marinobacter 12 12 100.0 | | | | |__ Shewanellaceae 17 17 100.0 | | | | | |__ Shewanella 17 17 100.0 | | | | |__ Pseudoalteromonadaceae 16 16 100.0 | | | | | |__ Pseudoalteromonas 15 15 100.0 | | | | |__ Idiomarinaceae 9 9 100.0 | | | | | |__ Idiomarina 9 9 100.0 | | | | |__ Colwelliaceae 6 6 100.0 | | | |__ Pseudomonadales 81 81 100.0 | | | | |__ Moraxellaceae 41 41 100.0 | | | | | |__ Acinetobacter 25 25 100.0 | | | | | |__ Psychrobacter 8 8 100.0 | | | | | |__ Moraxella 6 6 100.0 | | | | |__ Pseudomonadaceae 40 40 100.0 | | | | | |__ Pseudomonas 38 38 100.0 | | | |__ Oceanospirillales 73 72 98.6 | | | | |__ Oceanospirillaceae
    [Show full text]
  • Characterization of Environmental and Cultivable Antibiotic- Resistant Microbial Communities Associated with Wastewater Treatment
    antibiotics Article Characterization of Environmental and Cultivable Antibiotic- Resistant Microbial Communities Associated with Wastewater Treatment Alicia Sorgen 1, James Johnson 2, Kevin Lambirth 2, Sandra M. Clinton 3 , Molly Redmond 1 , Anthony Fodor 2 and Cynthia Gibas 2,* 1 Department of Biological Sciences, University of North Carolina at Charlotte, Charlotte, NC 28223, USA; [email protected] (A.S.); [email protected] (M.R.) 2 Department of Bioinformatics and Genomics, University of North Carolina at Charlotte, Charlotte, NC 28223, USA; [email protected] (J.J.); [email protected] (K.L.); [email protected] (A.F.) 3 Department of Geography & Earth Sciences, University of North Carolina at Charlotte, Charlotte, NC 28223, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-704-687-8378 Abstract: Bacterial resistance to antibiotics is a growing global concern, threatening human and environmental health, particularly among urban populations. Wastewater treatment plants (WWTPs) are thought to be “hotspots” for antibiotic resistance dissemination. The conditions of WWTPs, in conjunction with the persistence of commonly used antibiotics, may favor the selection and transfer of resistance genes among bacterial populations. WWTPs provide an important ecological niche to examine the spread of antibiotic resistance. We used heterotrophic plate count methods to identify Citation: Sorgen, A.; Johnson, J.; phenotypically resistant cultivable portions of these bacterial communities and characterized the Lambirth, K.; Clinton,
    [Show full text]
  • Wedding Higher Taxonomic Ranks with Metabolic Signatures Coded in Prokaryotic Genomes
    Wedding higher taxonomic ranks with metabolic signatures coded in prokaryotic genomes Gregorio Iraola*, Hugo Naya* Corresponding authors: E-mail: [email protected], [email protected] This PDF file includes: Supplementary Table 1 Supplementary Figures 1 to 4 Supplementary Methods SUPPLEMENTARY TABLES Supplementary Tab. 1 Supplementary Tab. 1. Full prediction for the set of 108 external genomes used as test. genome domain phylum class order family genus prediction alphaproteobacterium_LFTY0 Bacteria Proteobacteria Alphaproteobacteria Rhodobacterales Rhodobacteraceae Unknown candidatus_nasuia_deltocephalinicola_PUNC_CP013211 Bacteria Proteobacteria Gammaproteobacteria Unknown Unknown Unknown candidatus_sulcia_muelleri_PUNC_CP013212 Bacteria Bacteroidetes Flavobacteriia Flavobacteriales NA Candidatus Sulcia deinococcus_grandis_ATCC43672_BCMS0 Bacteria Deinococcus-Thermus Deinococci Deinococcales Deinococcaceae Deinococcus devosia_sp_H5989_CP011300 Bacteria Proteobacteria Unknown Unknown Unknown Unknown micromonospora_RV43_LEKG0 Bacteria Actinobacteria Actinobacteria Micromonosporales Micromonosporaceae Micromonospora nitrosomonas_communis_Nm2_CP011451 Bacteria Proteobacteria Betaproteobacteria Nitrosomonadales Nitrosomonadaceae Unknown nocardia_seriolae_U1_BBYQ0 Bacteria Actinobacteria Actinobacteria Corynebacteriales Nocardiaceae Nocardia nocardiopsis_RV163_LEKI01 Bacteria Actinobacteria Actinobacteria Streptosporangiales Nocardiopsaceae Nocardiopsis oscillatoriales_cyanobacterium_MTP1_LNAA0 Bacteria Cyanobacteria NA Oscillatoriales
    [Show full text]
  • Endogenous Enterobacteriaceae Underlie Variation in Susceptibility to Salmonella Infection
    ARTICLES https://doi.org/10.1038/s41564-019-0407-8 Endogenous Enterobacteriaceae underlie variation in susceptibility to Salmonella infection Eric M. Velazquez1, Henry Nguyen1, Keaton T. Heasley1, Cheng H. Saechao1, Lindsey M. Gil1, Andrew W. L. Rogers1, Brittany M. Miller1, Matthew R. Rolston1, Christopher A. Lopez1,2, Yael Litvak 1, Megan J. Liou1, Franziska Faber 1,3, Denise N. Bronner1, Connor R. Tiffany1, Mariana X. Byndloss1,2, Austin J. Byndloss1 and Andreas J. Bäumler 1* Lack of reproducibility is a prominent problem in biomedical research. An important source of variation in animal experiments is the microbiome, but little is known about specific changes in the microbiota composition that cause phenotypic differences. Here, we show that genetically similar laboratory mice obtained from four different commercial vendors exhibited marked phenotypic variation in their susceptibility to Salmonella infection. Faecal microbiota transplant into germ-free mice repli- cated donor susceptibility, revealing that variability was due to changes in the gut microbiota composition. Co-housing of mice only partially transferred protection against Salmonella infection, suggesting that minority species within the gut microbiota might confer this trait. Consistent with this idea, we identified endogenous Enterobacteriaceae, a low-abundance taxon, as a keystone species responsible for variation in the susceptibility to Salmonella infection. Protection conferred by endogenous Enterobacteriaceae could be modelled by inoculating mice with probiotic Escherichia coli, which conferred resistance by using its aerobic metabolism to compete with Salmonella for resources. We conclude that a mechanistic understanding of phenotypic variation can accelerate development of strategies for enhancing the reproducibility of animal experiments. recent survey suggests that the majority of researchers Results have tried and failed to reproduce their own experiments To determine whether genetically similar strains of mice obtained A or experiments from other scientists1.
    [Show full text]
  • Exogenous Protein As an Environmental Stimuli of Biofilm Formation in Select Bacterial Strains
    Exogenous Protein as an Environmental Stimuli of Biofilm Formation in Select Bacterial Strains Donna Ye1, Lekha Bapu1, Mariane Mota Cavalcante2, Jesse Kato1, Maggie Lauria Sneideman3, Kim Scribner4, Thomas Loch4 & Terence L. Marsh1* 1 Department of Microbiology and Molecular Genetics, Michigan State University, East Lansing, MI 2 Department of Biology, Universidade Federal de São Carlos, Sorocaba - SP, Brazil 3 Department of Biology, Kalamazoo College, Kalamazoo MI 4 Department of Fisheries and Wildlife, Michigan State University, East Lansing, MI *Correspondence may be addressed to T.L. Marsh ([email protected]) Supplemental Files. Figure 1. Phylogenetic tree of Serratia isolates (RL1-RL16). Table 1. Phylogenetic affiliation of Serratia isolates determined by Ribosomal Database Project Classifier. Table 2. Phylogenetic affiliation of Serratia isolates determined by Ribosomal Database Project Sequence Match. Classifier: RDP Naive Bayesian rRNA Classifier Version 2.11 Taxonomical Hierarchy: RDP 16S rRNA training set 16 Confidence threshold (for classification to Root ONLY): 80% Symbol +/- indicates predicted seQuence orientation RL1 Bacteria 100% Proteobacteria 100% Gammaproteobacteria 100% Enterobacteriales 100% Enterobacteriaceae 100% Serratia 100% RL2 Bacteria 100% Proteobacteria 100% Gammaproteobacteria 100% Enterobacteriales 100% Enterobacteriaceae 100% Serratia 100% RL3 Bacteria 100% Proteobacteria 100% Gammaproteobacteria 100% Enterobacteriales 100% Enterobacteriaceae 100% Serratia 100% RL4 Bacteria 100% Proteobacteria 100% Gammaproteobacteria
    [Show full text]
  • Carbapenem-Resistant Enterobacteriaceae a Microbiological Overview of (CRE) Carbapenem-Resistant Enterobacteriaceae
    PREVENTION IN ACTION MY bugaboo Carbapenem-resistant Enterobacteriaceae A microbiological overview of (CRE) carbapenem-resistant Enterobacteriaceae. by Irena KennelEy, PhD, aPRN-BC, CIC This agar culture plate grew colonies of Enterobacter cloacae that were both characteristically rough and smooth in appearance. PHOTO COURTESY of CDC. GREETINGS, FELLOW INFECTION PREVENTIONISTS! THE SCIENCE OF infectious diseases involves hundreds of bac- (the “bug parade”). Too much information makes it difficult to teria, viruses, fungi, and protozoa. The amount of information tease out what is important and directly applicable to practice. available about microbial organisms poses a special problem This quarter’s My Bugaboo column will feature details on the CRE to infection preventionists. Obviously, the impact of microbial family of bacteria. The intention is to convey succinct information disease cannot be overstated. Traditionally the teaching of to busy infection preventionists for common etiologic agents of microbiology has been based mostly on memorization of facts healthcare-associated infections. 30 | SUMMER 2013 | Prevention MULTIDRUG-resistant GRAM-NEGative ROD ALert: After initial outbreaks in the northeastern U.S., CRE bacteria have THE CDC SAYS WE MUST ACT NOW! emerged in multiple species of Gram-negative rods worldwide. They Carbapenem-resistant Enterobacteriaceae (CRE) infections come have created significant clinical challenges for clinicians because they from bacteria normally found in a healthy person’s digestive tract. are not consistently identified by routine screening methods and are CRE bacteria have been associated with the use of medical devices highly drug-resistant, resulting in delays in effective treatment and a such as: intravenous catheters, ventilators, urinary catheters, and high rate of clinical failures.
    [Show full text]
  • The Characteristics of Gut Microbiota and Commensal Enterobacteriaceae Isolates in Tree Shrew
    Gu et al. BMC Microbiology (2019) 19:203 https://doi.org/10.1186/s12866-019-1581-9 RESEARCHARTICLE Open Access The characteristics of gut microbiota and commensal Enterobacteriaceae isolates in tree shrew (Tupaia belangeri) Wenpeng Gu1,2, Pinfen Tong1, Chenxiu Liu1, Wenguang Wang1, Caixia Lu1, Yuanyuan Han1, Xiaomei Sun1, De Xuan Kuang1,NaLi1 and Jiejie Dai1* Abstract Background: Tree shrew is a novel laboratory animal with specific characters for human disease researches in recent years. However, little is known about its characteristics of gut microbial community and intestinal commensal bacteria. In this study, 16S rRNA sequencing method was used to illustrate the gut microbiota structure and commensal Enterobacteriaceae bacteria were isolated to demonstrate their features. Results: The results showed Epsilonbacteraeota (30%), Proteobacteria (25%), Firmicutes (19%), Fusobacteria (13%), and Bacteroidetes (8%) were the most abundant phyla in the gut of tree shrew. Campylobacteria, Campylobacterales, Helicobacteraceae and Helicobacter were the predominant abundance for class, order, family and genus levels respectively. The alpha diversity analysis showed statistical significance (P < 0.05) for operational taxonomic units (OTUs), the richness estimates, and diversity indices for age groups of tree shrew. Beta diversity revealed the significant difference (P < 0.05) between age groups, which showed high abundance of Epsilonbacteraeota and Spirochaetes in infant group, Proteobacteria in young group, Fusobacteria in middle group, and Firmicutes in senile group. The diversity of microbial community was increased followed by the aging process of this animal. 16S rRNA gene functional prediction indicated that highly hot spots for infectious diseases, and neurodegenerative diseases in low age group of tree shrew (infant and young).
    [Show full text]
  • Final Risk Assessment of Escherichia Coli K-12 Derivatives (PDF)
    ATTACHMENT I--FINAL RISK ASSESSMENT OF ESCHERICHIA COLI K-12 DERIVATIVES (February 1997) I. INTRODUCTION Escherichia coli is one of a number of microorganisms which are normal inhabitants of the colons of virtually all warm- blooded mammals. E. coli belongs to the taxonomic family known as Enterobacteriaceae, which is one of the best-defined groups of bacteria. The strain E. coli K-12 is a debilitated strain which does not normally colonize the human intestine. It has also been shown to survive poorly in the environment, has a history of safe commercial use, and is not known to have adverse effects on microorganisms or plants. Because of its wide use as a model organism in research in microbial genetics and physiology, and its use in industrial applications, E. coli K-12 is one of the most extensively studied microorganisms. History of Commercial Use and Products Subject to TSCA Jurisdiction E. coli K-12 has a history of safe use. Its derivatives are currently used in a large number of industrial applications, including the production of specialty chemicals (e.g., L- aspartic, inosinic, and adenylic acids) and human drugs such as insulin and somatostatin (Dynamac, 1990). Further, E. coli can produce a number of specialty chemicals such as enzymes which would be regulated under TSCA. An insulin-like hormone for use as a component of cell culture media, resulting from a fermentation application in which E. coli was used as the recipient, has already been reviewed under TSCA (Premanufacture Notice P87-693). EPA recently reviewed a submission (94-1558) for use of E.
    [Show full text]
  • Treatment of Infections Due to MDR Gram-Negatives: Enterobacteriaceae, P.Aeruginosa and A. Baumannii; a Dead End?
    Treatment options for difficult-to-treat organisms: the case of MDR MDR Gram-negatives: Enterobacteriaceae , P.aeruginosa and A. baumannii Javier Garau, MD, PhD University of Barcelona © by author ESCMID Course, Primosten, September 2011 ESCMID Online Lecture Library OUTLINE • Scope of the problem • Risk factors for MDR infection • Impact on mortality • Antibiotic combinations • An example • How to use colistin© by author ESCMID Online Lecture Library • Increased recognition of successful antibiotic-resistant clones appearing in multiple geographic regions. • Patients with MDR GNB are at an increased risk for inappropriate empirical antimicrobial therapy, and studies have demonstrated that delays in appropriate antimicrobial treatment may be detrimental to patient outcomes • In one study, growth rates of most MDR isolates (n=33) were similar to that of the wild type, and two isolates (11%) were found to be hypermutable© (Tam by VHauthor et al. AAC 2010) ESCMID Online Lecture Library • Strains that are resistant to all antibiotics including polymixins are rare, although their incidence is increasing • Antibiotic combinations that yield some degree of susceptibility in vitro are the only recourse in such situations.© by author ESCMID Online Lecture Library Expansion of healthcare-associated carbapenem-non-susceptible Enterobacteriaceae in Europe: epidemiological scale and stages by country, as of July 2010 © by author ESCMID Online*Grundmann LectureH et al. Euro Surveill. Library 2010 OUTLINE • Scope of the problem • Risk factors for MDR infection • Impact on mortality • Antibiotic combinations • A real example • How to use colistin© by author ESCMID Online Lecture Library Clinical Prediction Tool To Identify Patients with P aeruginosa Pneumonia at Greatest Risk for MDR infection • Retrospective case-control study • Multidrug resistance defined as resistance to at least four classes of antipseudomonal agents © by author ESCMID LodiseOnline TP et al.Lecture AAC2007 Library Bivariate analysis of the relationship between clinical features and MDR P.
    [Show full text]
  • Supplementary Table 4. Otus Exhibiting Statistically Significant Differences in Abundance Between Pre and Post Pre-Vitamin D Treatment
    Supplementary Table 4. OTUs Exhibiting Statistically Significant Differences in Abundance between pre and post pre-Vitamin D treatment. Phylum Subphylum Family Accession P-Value Firmicutes Clostridia Unclassified DQ793674.1 0.0003 Firmicutes Clostridia Ruminococcus DQ441345.1 0.0010 Firmicutes Clostridia Acetivibrio EF686638.1 0.0014 Firmicutes Clostridia Ruminococcus EU768484.1 0.0019 WS6 WM1006 Unclassified DQ397467.1 0.0020 Firmicutes Clostridia Ruminococcus DQ798739.1 0.0021 Firmicutes Clostridia Unclassified EU468734.1 0.0023 Firmicutes Clostridia Ruminococcus EU774563.1 0.0023 Firmicutes Clostridia Ruminococcus EU469923.1 0.0023 Firmicutes Clostridia Clostridium EF095977.1 0.0028 Firmicutes Clostridia Eubacterium DQ795602.1 0.0030 Firmicutes Clostridia Ruminococcus EU774409.1 0.0031 Firmicutes Clostridia Ruminococcus EU381636.1 0.0033 Firmicutes Clostridia Ruminococcus EU467336.1 0.0033 Proteobacteria Alphaproteobacteria SAR11 EF573244.1 0.0037 Proteobacteria Alphaproteobacteria SAR11 EF572067.1 0.0037 Proteobacteria Alphaproteobacteria SAR11 EU805290.1 0.0038 Firmicutes Clostridia Ruminococcus DQ794950.1 0.0039 Firmicutes Clostridia Ruminococcus DQ797467.1 0.0041 Proteobacteria Alphaproteobacteria SAR11 EU802513.1 0.0041 Firmicutes Clostridia Ruminococcus EU747914.1 0.0041 Firmicutes Clostridia Faecalibacterium DQ777912.1 0.0042 Firmicutes Clostridia Ruminococcus EF402950.1 0.0046 Firmicutes Clostridia Unclassified EU507404.1 0.0046 Proteobacteria Alphaproteobacteria SAR11 EU804992.1 0.0049 Firmicutes Clostridia Ruminococcus EU460164.1
    [Show full text]
  • Esβl, Ampc and Carbapenemase Co-Production in Multi-Drug Resistant Gram-Negative Bacteria from HIV-Infected Patients in Southwestern Nigeria *Adeyemi, F
    ESBL, AmpC and carbapenemase co-production in Gram-negative bacteria Afr. J. Clin. Exper. Microbiol. 2021; 22 (1): 38-51 Adeyemi & Akinde. Afr. J. Clin. Exper. Microbiol. 2021; 22 (1): 38 - 51 https://www.afrjcem.org African Journal of Clinical and Experimental Microbiology. ISSN 1595-689X Jan. 2021; Vol. 22; No 1. AJCEM/2047. https://www.ajol.info/index.php/ajcem Copyright AJCEM 2021: https://dx.doi.org/10.4314/ajcem.v22i1.6 Original Article Open Access ESβL, AmpC and carbapenemase co-production in multi-drug resistant Gram-negative bacteria from HIV-infected patients in southwestern Nigeria *Adeyemi, F. M., and Akinde, S. B. Department of Microbiology, Faculty of Basic and Applied Sciences, Osun State University, Osogbo, Nigeria *Correspondence to: [email protected]; +234 803 494 0747 Abstract: Background: The rising global emergence of Gram-negative bacteria (GNB) producing β-lactam hydrolysing enzymes in clinical infections constitutes a growing public health threat. This study investigated the occurrence of co-production of extended spectrum β-lactamase (ESβL), AmpC β-lactamases, and carbapenemases among GNB isolated from HIV- infected patients in two tertiary healthcare facilities in southwest Nigeria. Methodology: A total of 115 GNB isolates previously recovered from HIV-infected patients at the Obafemi Awolowo University Teaching Hospitals Complex, Ile-Ife, and the State Specialist Hospital, Akure, were investigated. The isolates were characterized to species level with the Microbact 24E kit and screened for ESβL production using the double-disc test (DDT) and combination disc methods, AmpC using modified Hodge test (MHT) and AmpC EDTA disc, and carbapenemase production using the MHT and EDTA disc test.
    [Show full text]